|Articles|May 1, 2013
Targeted Therapies in Oncology
- May 2013
- Volume 2
- Issue 3
Full Version of the May 2013 Issue
Full version of the May 2013 Targeted Therapy News
Advertisement
Targeted Therapy Newscovers the most important developments in cancer care today, personalized medicine and targeted therapies. The publication is strongly committed to providing oncology healthcare professionals the information and resources they need to deliver the best possible treatment to their patients
This issue features articles on:
- Key targeted trials being presented at ASCO
- Nongenetic mechanisms of cancer cell diversity and treatment response
- Platinum resistance in ovarian cancer
- HER2-targeted agents in NSCLC
Articles in this issue
about 13 years ago
Bundled Payment: Practice Savior or Killer?about 13 years ago
Notch Holds Promise, but Presents Obstacles as Cancer Targetabout 13 years ago
Spotlight on Novel Agents in Early Developmentabout 13 years ago
Treating Elderly Patients With CLLabout 13 years ago
Biomarkers Still Needed in Prostate Cancerabout 13 years ago
New Developments in Oral Targeted Agents for Advanced Colorectal Cancerabout 13 years ago
Numerous Drug Classes Studied for Use in Follicular and Other LymphomasAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Clears Pen Device for Interferon Therapy in Polycythemia Vera
2
FDA Rejects Edotreotide PET Imaging Kit Over Manufacturing Concerns
3
Deep Responses Support Push for CAR T-Cell Therapy in AL Amyloidosis
4
FDA Accepts RP1 BLA Resubmission for Advanced Melanoma
5